# Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML

> **NCT04490707** · PHASE3 · UNKNOWN · sponsor: **Ge Zheng** · enrollment: 60 (estimated)

## Conditions studied

- Acute Myeloid Leukemia in Remission

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT04490707
- **Lead sponsor:** Ge Zheng
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04490707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04490707, "Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04490707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*